Dergiler / Diagnostic and Interventional Radiology / 2018 / Cilt: 24 - Sayı: 5

Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments

Sayfa
268–275
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Older patients and those with poor sexual function need to be counseledregarding the risk of erectile dysfunction.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:PURPOSEWe aimed to evaluate the genitourinary function and quality of life (QoL) following the ablationof different prostate segments with irreversible electroporation (IRE) for localized prostate cancer(PCa).METHODSSixty patients who received primary focal IRE for organ-confined PCa were recruited for thisstudy.
📊
Temel Bulgular & Veri:Data were prospectively collected at baseline,3, 6, and 12 months using the expanded prostate cancer index composite, American UrologicalAssociation symptom score, SF-12 physical and mental component summary surveys.
💡
Sonuç & Katkı:Older patients and those with poor sexual function need to be counseledregarding the risk of erectile dysfunction.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

PURPOSEWe aimed to evaluate the genitourinary function and quality of life (QoL) following the ablationof different prostate segments with irreversible electroporation (IRE) for localized prostate cancer(PCa).METHODSSixty patients who received primary focal IRE for organ-confined PCa were recruited for thisstudy. Patients were evaluated for genitourinary function and QoL per prostate segment treated(anterior vs. posterior, apex vs. base vs. apex-to-base, unilateral vs. bilateral). IRE system settingsand patient characteristics were compared between patients with preserved vs. those with impairederectile function and urinary continence. Data were prospectively collected at baseline,3, 6, and 12 months using the expanded prostate cancer index composite, American UrologicalAssociation symptom score, SF-12 physical and mental component summary surveys. Differenceover time within segments per questionnaire was evaluated using the Wilcoxon’s signed ranktest. Outcome differences between segments were assessed using covariance models. Baselinemeasurements included questionnaire scores, age, and prostate volume.RESULTSThere were no statistically significant changes over time for overall urinary (P = 0.07–0.89), bowel(P = 0.06–0.79), physical (P = 0.18–0.71) and mental (P = 0.45–0.94) QoL scores within each segment.Deterioration of sexual function scores was observed at 6 months within each segment(P = 0.001–0.16). There were no statistically significant differences in QoL scores between prostatesegments (P = 0.08–0.97). Older patients or those with poor baseline sexual function at timeof treatment were associated with a greater risk of developing erectile dysfunction.CONCLUSIONIRE is a feasible modality for all prostate segments without any significantly different effect onthe QoL outcomes. Older patients and those with poor sexual function need to be counseledregarding the risk of erectile dysfunction.

🔖

Bu Makaleye Atıf Yap

SCHELTEMA, M. J., CHANG, J. I., BOS, W. V. D., GİELCHİNSKY, I., NGUYEN, T. V., REİJKE, T. M. D., SİRİWARDANA, A. R., BÖHM, M., ROSETTE, J. J. D. L., STRİCKER, P. D. (2018). Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagnostic and Interventional Radiology, Cilt: 24 - Sayı: 5, 268–275. https://ajindex.com/articles/350028

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Donaldson I, Alonzi R, Barratt D, et al. Focal therapy: patients, interventions, and outcomes- a report from a consensus meeting. Eur Urol 2015
  2. 771–777. [CrossRef ] 2. Ahmed HU, Zacharakis E, Dudderidge T, et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009
  3. 19–26. [CrossRef ] 3. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008
  4. 554– 558. [CrossRef ] 4. Matsuoka Y, Numao N, Saito K, et al. Candidate selection for quadrant-based focal ablation through a combination of diffusion- weighted magnetic resonance imaging and prostate biopsy. BJU Int 2016
  5. 94– 101. [CrossRef ] 5. Valerio M, Cerantola Y, Eggener SE, et al. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 2017
  6. 17–34. [CrossRef ] 6. Sivaraman A, Barret E. Focal therapy for prostate cancer: an “À la Carte” approach. Eur Urol 2016
  7. 2015–2017. [CrossRef ] 7. Ting F, Tran M, Böhm M, et al. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 2016
  8. 46–52. [CrossRef ] 8. Murray KS, Ehdaie B, Musser J, et al. Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer. J Urol 2016
  9. 883–890. [CrossRef ] 9. Valerio M, Stricker PD, Ahmed HU, et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 2014
  10. 343–347. [CrossRef ] 10. Valerio M, Dickinson L, Ali A, et al. Nanoknife electroporation ablation trial (NEAT): a prospective development study investigating focal irreversible electroporation in men with localised prostate cancer. J Urol 2017
  11. 647–654. [CrossRef ] 11. van den Bos W, De Bruin D, Veelo D, et al. Quality of life and safety outcomes following irreversible electroporation treatment for prostate cancer: results from a phase I-Ii study. J Cancer Sci Ther 2015
  12. 312–321. 12. van den Bos W, Scheltema MJ, Siriwardana AR, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int 2018
  13. 716–724. [CrossRef ] 13. Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2